Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B

Basit Öğe Kaydı
dc.authorscopusid6603946461
dc.authorscopusid26040768900
dc.authorscopusid36186191800
dc.authorscopusid36608138300
dc.authorscopusid6602981512
dc.authorscopusid58602450200
dc.authorscopusid36981727800
dc.contributor.authorKoklu, Seyfettin
dc.contributor.authorGulsen, Murat Taner
dc.contributor.authorTuna, Yasar
dc.contributor.authorKoklu, Hayretdin
dc.contributor.authorYuksel, Osman
dc.contributor.authorDemir, Mehmet
dc.contributor.authorGuner, Rahmet
dc.date.accessioned2024-09-19T15:48:49Z
dc.date.available2024-09-19T15:48:49Z
dc.date.issued2015
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractSummary Background Results are conflicting with respect to the renal effects of anti-viral agents used for hepatitis B virus infection. Aim To compare short and long-term renal effects in real-life settings and to determine risk factors for renal impairment during treatment. Methods 2221 treatment-naïve patients were enrolled. Among these, 895 (302 lamivudine, 27 telbivudine, 282 entecavir, 273 tenofovir and 11 adefovir initiated patients) had 'repeated measures' of creatinine (baseline, 1st, 6th, 12th and 24th month of treatment). Telbivudine and adefovir groups were excluded from further analysis because of the low number of patients. We calculated the glomerular filtration rate (GFR) using the Modification of Diet in Renal Disease (MDRD) formula at each time point. Hypophosphataemia was also recorded. Risk factors for renal impairment were analysed. Results Tenofovir caused a decline in GFR at each time point when compared to baseline levels. However, lamivudine and entecavir did not change GFR. GFR-shifting from ?90 to 60-89 mL/min/1.73 m2 was comparable among groups. The proportion of patients whose baseline creatinine increased more than 25% was comparable among all anti-virals. GFR showed a decline in patients who switched from entecavir to tenofovir. One patient with compensated cirrhosis needed to change from tenofovir because of renal safety. Seven and three patients developed transient hypophosphataemia in the tenofovir and lamivudine groups, respectively. Conclusions Although tenofovir caused a decline in GFR, differences between the anti-viral agents do not appear to be so impressive. In patients with and without renal risk factors at baseline, there is no impact of anti-virals, including tenofovir. © 2014 John Wiley & Sons Ltd.en_US
dc.identifier.doi10.1111/apt.13036
dc.identifier.endpage319en_US
dc.identifier.issn0269-2813
dc.identifier.issue3en_US
dc.identifier.pmid25982037en_US
dc.identifier.scopus2-s2.0-84920729292en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage310en_US
dc.identifier.urihttps://doi.org/10.1111/apt.13036
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15319
dc.identifier.volume41en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAdulten_US
dc.subjectAntiviral Agentsen_US
dc.subjectCreatinineen_US
dc.subjectFemaleen_US
dc.subjectGlomerular Filtration Rateen_US
dc.subjectHepatitis B virusen_US
dc.subjectHepatitis B, Chronicen_US
dc.subjectHumansen_US
dc.subjectLiver Cirrhosisen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectRenal Insufficiencyen_US
dc.subjectRisken_US
dc.subjectadefoviren_US
dc.subjectantivirus agenten_US
dc.subjectcreatinineen_US
dc.subjectentecaviren_US
dc.subjectlamivudineen_US
dc.subjectphosphateen_US
dc.subjecttelbivudineen_US
dc.subjecttenofoviren_US
dc.subjectcreatinineen_US
dc.subjectadulten_US
dc.subjectArticleen_US
dc.subjectcreatinine blood levelen_US
dc.subjectdrug safetyen_US
dc.subjectdrug substitutionen_US
dc.subjectdrug withdrawalen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjectglomerulus filtration rateen_US
dc.subjecthepatitis Ben_US
dc.subjecthumanen_US
dc.subjecthypophosphatemiaen_US
dc.subjectkidney diseaseen_US
dc.subjectliver cirrhosisen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmortalityen_US
dc.subjectrisk assessmenten_US
dc.subjectrisk factoren_US
dc.subjectsample sizeen_US
dc.subjectchemically induceden_US
dc.subjectcomparative studyen_US
dc.subjectHepatitis B virusen_US
dc.subjectHepatitis B, Chronicen_US
dc.subjectisolation and purificationen_US
dc.subjectliver cirrhosisen_US
dc.subjectmetabolismen_US
dc.subjectmiddle ageden_US
dc.subjectRenal Insufficiencyen_US
dc.subjectrisken_US
dc.titleDifferences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis Ben_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
[ N/A ]
İsim:
Tam Metin / Full Text
Boyut:
328.19 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu